![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
1. 367-21-5
2. 3-chloro-4-fluorobenzenamine
3. Benzenamine, 3-chloro-4-fluoro-
4. 3-chloro-4-fluorophenylamine
5. 3-chloro-4-fluoro-phenylamine
6. Aniline, 3-chloro-4-fluoro-
7. 3-chloro-4-fluoro Aniline
8. 4-fluoro-3-chloroaniline
9. 3-chloro-4-fluoro-aniline
10. 7l63cc70uq
11. 3-chloro-4-fluoroaniline(chunks Or Pellets)
12. Nsc-10290
13. Mfcd00007767
14. Unii-7l63cc70uq
15. Einecs 206-682-8
16. Nsc 10290
17. Gefitinib Impurity V
18. 3-chloro4-fluoroaniline
19. Norfloxacin Intermediates
20. 3-chloro-4-fluoroanilin
21. 3-chloro-4-flouroaniline
22. 3-chloro4-fluoro-aniline
23. 4-fluoro-3-chloro-aniline
24. Schembl9602
25. 3chloro-4-fluoro-phenylamine
26. 4-fluoro-3-chlorophenylamine
27. 4-fluoro-3-chlorophenyl Amine
28. M-chloro-p-fluoroaniline
29. 4-fluoro-3-chloro Phenyl Amine
30. Dtxsid0038754
31. 3-chloro-4-fluoroaniline, 98%
32. Zinc157622
33. Act09538
34. Bcp26715
35. Nsc10290
36. Stl164339
37. Akos000119505
38. Ac-2469
39. Cs-w009142
40. Ps-8955
41. Sb00006
42. Db-023935
43. Am20060177
44. Ft-0615380
45. 67c215
46. A15531
47. C-3925
48. P19616
49. Q27268500
50. F2190-0461
51. 3-chloro-4-fluoroaniline;benzenamine, 3-chloro-4-fluoro-
Molecular Weight | 145.56 g/mol |
---|---|
Molecular Formula | C6H5ClFN |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 2 |
Rotatable Bond Count | 0 |
Exact Mass | 145.0094550 g/mol |
Monoisotopic Mass | 145.0094550 g/mol |
Topological Polar Surface Area | 26 Ų |
Heavy Atom Count | 9 |
Formal Charge | 0 |
Complexity | 99.1 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.